Nivolumab and Ipilimumab in Treating Patients With Metastatic Recurrent Major or Minor Salivary Gland Cancer

Conditions:   Major Salivary Gland Carcinoma;   Minor Salivary Gland Carcinoma;   Recurrent Salivary Gland Carcinoma;   Stage IV Major Salivary Gland Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVC Major Salivary Gland Carcinoma
Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
Sponsors:   Northwestern University;   Bristol-Myers Squibb;   National Cancer Institute (NCI)
Not yet recruiting - verified March 2017

http://ift.tt/2qrgMOa